Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of... The post SOHO 2021: amyloidosis treatment updates appeared first on VJHemOnc.

VJHemOnc Podcast

SOHO 2021: amyloidosis treatment updates

Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia,... The post IACH 2021: CAR-T in clinical practice appeared first on VJHemOnc.

IACH 2021: CAR-T in clinical practice

The treatment of chronic myeloid leukemia (CML) has substantially evolved since the FDA approval of the tyrosine kinase inhibitor imatinib... The post Unmet needs and recent updates in CML appeared first on VJHemOnc.

Unmet needs and recent updates in CML

Continuous therapy has been a key aspect of the standard of care approaches for the treatment of multiple myeloma for... The post IMW 2021: treatment-free intervals in multiple myeloma appeared first on VJHemOnc.

IMW 2021: treatment-free intervals in multiple myeloma

The management of chronic lymphocytic leukemia (CLL) has evolved drastically over the last few years, with the introduction of novel... The post Highlights from iwCLL 2021 appeared first on VJHemOnc.

Highlights from iwCLL 2021

Measurable residual disease (MRD) is emerging as an important prognostic marker in the management of multiple myeloma. Promising clinical evidence... The post IMW 2021: MRD in myeloma appeared first on VJHemOnc.

IMW 2021: MRD in myeloma

Autologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades;... The post CAR-T vs bispecifics: replacing ASCT in myeloma appeared first on VJHemOnc.

CAR-T vs bispecifics: replacing ASCT in myeloma

Antibody therapies are rapidly transforming the treatment landscape of non-Hodgkin lymphoma (NHL). Since the development of rituximab as an anti-CD20... The post EHA 2021: antibody therapies for NHL appeared first on VJHemOnc.

EHA 2021: antibody therapies for NHL

A significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older... The post EHA 2021: updates on novel agents for AML appeared first on VJHemOnc.

EHA 2021: updates on novel agents for AML

Janus kinase (JAK) inhibitors are becoming an increasingly prominent class of drug in the treatment of myeloproliferative neoplasms (MPNs), in... The post Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs appeared first on VJHemOnc.

Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs

Great progress has been made in the treatment of acute lymphocytic leukemia (ALL), primarily owing to the development of targeted... The post EHA 2021: targeted therapies for ALL appeared first on VJHemOnc.

EHA 2021: targeted therapies for ALL

Many clinical trials are currently investigating the potential benefits of interferons in the treatment of myeloproliferative neoplasms (MPNs), in particular... The post Texas MPN Workshop 2021: updates on interferons for MPNs appeared first on VJHemOnc.

Texas MPN Workshop 2021: updates on interferons for MPNs

Real-world data gained through scientific studies is essential in the advancement of treatments for all hematological malignancies. Historically, pharmaceutical companies... The post EHA 2021: real-world data on myeloma, lymphoma and CLL appeared first on VJHemOnc.

EHA 2021: real-world data on myeloma, lymphoma and CLL

Over the past two decades the treatment landscape for non-Hodgkin lymphoma (NHL) has rapidly evolved, with the development of Bruton’s... The post Novel BTK inhibitors for NHL appeared first on VJHemOnc.

Novel BTK inhibitors for NHL

Research into the treatment of non-Hodgkin lymphoma (NHL) has made great progress within the last decade, with clinical trials such... The post Latest updates on T-cell therapies for non-Hodgkin lymphoma appeared first on VJHemOnc.

Latest updates on T-cell therapies for non-Hodgkin lymphoma

The video journal of hematological oncology

hubhopper

VJHemOnc Podcast

hubhopper